Aratana Therapeutics Inc. diskutieren

folgen

a +

zu folgen

Die Analysten bieten Prognosen für Aratana Therapeutics, Inc. FY2021 Gewinn $ PETX

Aranta is a long term growth play in a growing market for therapeutics for dogs and cats

Product Portfolio:

The company is well positioned to take advantage of the secular trend of consistently growing spending on dogs and cats. The company has three approved and launched products in its portfolio now.

Galliprant:

This compound is approved for the control of pain and inflammation associated with osteoarthritis in dogs. It is marketed and distributed by Elanco, a division of Eli Lilly.

The company receives a variety of milestones and royalties from Elanco through a collaboration deal around Galliprant.

Nocita:

This is a wholly owned compound approved as a post-operative anesthetic for cranial cruciate ligament surgery in dogs.

Entyce:

Another wholly owned compound approved to trigger appetite stimulation in dogs. Entyce should
find a receptive market.  According to recent surveys, two thirds of veterinarians are not satisfied with current products on the market to treat this condition.

SektorPharmazeutika

Am ^27. März 2018 aufgerüstet Forschungsunternehmen Stifel die Bewertung der Aktien der Gesellschaft von „Hold“ auf „Buy“ mit einem Kursziel von $ 8 pro Aktie.

Secteur Produits pharmaceutiques Agenda 14/03 Publication de résultats

Chance

oder weiterer Kursverlust?